The global treatment-resistant hypertension management market is poised for substantial growth, with forecasts predicting an expansion from US$ 43 million in 2023 to US$ 159.41 million by 2033. This impressive increase represents a compound annual growth rate (CAGR) of 14%, reflecting a notable acceleration from the 11% CAGR recorded between 2018 and 2022.
Treatment-resistant hypertension is defined as high blood pressure that remains uncontrolled despite the concurrent use of three or more antihypertensive medications. TRH not only poses severe health risks, including heightened chances of cardiovascular events and end-organ damage but also presents significant challenges in management for healthcare providers.
Get Recently Updated Report of Market as Sample Copy! https://www.futuremarketinsights.com/reports/sample/rep-gb-16829
The considerable growth projected in the TRH management market can be attributed to several key factors:
- Increasing Prevalence: The number of individuals diagnosed with hypertension is on the rise globally, thereby increasing the population of patients who potentially develop treatment-resistant forms of the condition.
- Enhanced Awareness: There is a growing recognition of the risks associated with uncontrolled hypertension, which has heightened the demand for more effective management solutions.
- Technological and Pharmacological Advancements: Innovations in medical technology and new pharmacological developments have led to the introduction of novel treatment options, expanding the market further.
The surge in research and development activities around TRH management is a testament to the urgent need for innovative and effective treatments that can address the complexities of this condition. Industry stakeholders are increasingly focused on developing strategies that can deliver better health outcomes and improve the quality of life for those affected by this challenging form of hypertension.
As the TRH management market continues to evolve, it holds significant potential for healthcare providers, patients, and medical technology firms specializing in hypertension and cardiovascular care. The next decade is likely to witness the introduction of more advanced and patient-centric solutions that will redefine how treatment-resistant hypertension is managed across the globe.
Key Takeaways from the Market Study:
- From 2018 to 2022, the Treatment-Resistant Hypertension Management market grew at a CAGR of 11%.
- The global Treatment-Resistant Hypertension Management market is expected to grow with a 14% CAGR during 2023 to 2033.
- As of 2033, the Treatment-Resistant Hypertension Management Market is expected to reach US$ 159.41 Million.
- According to the FMI analysis, the hospitals segment accounts for the largest market share.
- North America is expected to possess 40% market share for the Treatment-Resistant Hypertension Management market.
- The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Treatment-Resistant Hypertension Management.” says an FMI analyst
Methodology Details Just a Click Away: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16829
Market Competition:
Key players in the market include companies such as Competition Deep Dive, Janssen Biotech, Quantum Genomics SA, CinCor Pharma, Ionis Pharmaceuticals, Vifor Pharma, KBP Biosciences, Abbott, Kona Medical, Inc., Medtronic along with healthcare providers and technology companies among other global players.
- The findings of a phase II trial, conducted by a researcher from Queen Mary University of London in collaboration with colleagues at CinCor Pharma, USA, indicate that a novel drug named Baxdrostat can effectively decrease high blood pressure (hypertension) in patients who may not respond to existing treatments for the condition. Baxdrostat functions by hindering the body’s production of aldosterone, a hormone that governs the salt levels in the body. The drug successfully reduced the levels of aldosterone in the blood and urine. The study demonstrated that Baxdrostat resulted in a considerable decrease in blood pressure among patients who exhibit resistance to standard medications for hypertension, which is attributed, in part, to excessive production of the aldosterone hormone.
More Insights Available:
FMI, in its new offering, presents an unbiased analysis of the global Treatment-Resistant Hypertension Management market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights on the basis of Distribution Channel, Treatment & Region.
Key Segments Profiled in the Treatment-Resistant Hypertension Management Industry Survey
Treatment:
- Diuretic therapy
- Combination therapy
- Mineralocorticoid receptor antagonists
Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
Get Exclusive Purchase Now to Access: https://www.futuremarketinsights.com/checkout/16829
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube